Table 1.
Selection of ongoing/planned trials for venetoclax-based therapy in previously untreated CLL
| Active disease | Study ID | Experimental agent(s) and comparator | N | Status | Trial registration |
|---|---|---|---|---|---|
| FLAIR | Fludarabine-cyclophosphamide-rituximab vs ibrutinib vs ibrutinib-venetoclax | 1516 | Recruiting | ISRCTN01844152 | |
| CLL13 | Fludarabine-cyclophosphamide-rituximab/bendamustine-rituximab vs venetoclax-rituximab vs venetoclax-obinutuzumab vs obinutuzumab-ibrutinib-venetoclax | 920 | Recruitment completed | NCT02950051 | |
| National Cancer Institute (ECOG 9161) | Ibrutinib-obinutuzumab vs obinutuzumab-ibrutinib-venetoclax in untreated younger patients | 720 | Recruiting | NCT03701282 | |
| National Cancer Institute (Alliance 041702) | Ibrutinib-obinutuzumab vs obinutuzumab-ibrutinib-venetoclax in untreated older patients | 454 | Recruiting | NCT03737981 | |
| CLL17 | Ibrutinib vs venetoclax-obinutuzumab vs ibrutinib-venetoclax | 920 | In preparation | EudraCT 2019-003854-99 |
All are phase 3, multicenter, open-label trials. No results have been submitted.
Active disease, according to iwCLL criteria (ref. 19); ECOG, Eastern Cooperative Oncology Group.